Program

IKMG Research Group - 4^th International Meeting

IKMG 4th Meeting - PROGRAM.pdf

IKMG 4th Meeting - ABSTRACTS.pdf

Thursday May 23 2019
7:00 am: Registration and Breakfast

8:00 am: Opening remarks

8:15 am:    MGRS-related kidney diseases
                           1. The updated classification of MGRS-related kidney diseases: Nelson Leung
                                2. State of the art of the techniques for the diagnosis of M-Ig related kidney diseases: Vivette D’Agati

9:15 am:    Proliferative Glomerulonephritis with non-organized monoclonal immunoglobulin deposits (PGNMID)
                              1. Pathology of PGNMID: Samih Nasr
                            2. Clinical and hematological characteristics of PGNMID: Jonathan Hogan

3. Update on treatment of PGNMID: Nelson Leung

10:45 am: Break

11:00 am: Light Chain Cast Nephropathy
                            1. Pathology of light chain cast nephropathy: Virginie Royal
             2. Current criteria for renal response in light chain cast nephropathy: Efstathios Kastritis
             3. Treatment of light chain cast nephropathy/MYRE study: Frank Bridoux

12:30 pm: Lunch

2:00 pm:    Biological and diagnosis
                          1. Update on monoclonal protein detection/measurement: Mass spectrometry: David Murray
   2. Proteomics in the diagnosis of M-Ig related kidney diseases: Surendra Dasari
   3. Immunoglobulin Repertoire Sequencing (RepSeq): A new tool for diagnosis and treatment
follow-up in monoclonal gammopathy of clinical significance: Christophe Sirac
3:30 pm:    Break

4:00 pm: Oral Communications

1. Free light chain-induced proximal tubule injury is mediated via toll-like receptors 2/4 through generation of HMGB1: Vecihi Batuman

2. Monoclonal gammopathies and their significance: A retrospective analysis of monoclonal gammopathy and renal disease: Cindy Varga

3. Light chain deposition disease (LCDD) and renal light chain (AL) amyloidosis: different clinical presentation and renal outcome: Paolo Milani

4. Management of first relapse non IgM light chain amyloidosis: a french multicentric retrospective study: Camille Villesuzanne

5. Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission But With Persistent Renal Disease: Cindy Varga

6. Renal histopathology spectrum of Monoclonal Gammopathy of Renal Significance : A single referral lab experience: Rajan Duggal

7. Contribution in the understanding of Heavy Chain Deposition Disease molecular mechanisms: Sébastien Bender

8. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) : a case series of 71 patients: Vincent Javaugue

9. Diagnostic Pathway in Patients Presenting with Acute Kidney Injury Secondary to de novo Multiple Myeloma: A Two Centre Experience: Ritika Rana

10. Abnormal monoclonal immunoglobulins in plasma cell proliferations: a new animal model to study their role in plasma cell survival: Maria Victoria Ayala

6:00 pm: Reception and Posters

8:00 pm: Dinner

Friday May 24 2019

7:00 am: Breakfast

8:00 am: Basic Science
1. Make it count: technical considerations and initial findings for accurate quantitative comparisons
of urinary extracellular vesicles to determine minimal residual kidney disease in AL amyloidosis: Marina Ramirez Alvarado

2. Understanding mesangial damage and repair in light-chain associated mesangiopathy: Guillermo Herrera

3. C3 glomerulopathy, thrombotic microangiopathy and monoclonal immunoglobulin: Sophie Chauvet
4. Pathophysiology of light chain cast nephropathy: Paul Sanders

10:30 am: Break

10:45 am: AL Amyloidosis
1. Pitfalls in the diagnosis of AL amyloidosis: Ashutosh Wechalekar
2. Update on the treatments of AL amyloidosis: Arnaud Jaccard

3. Organ transplantation in Amyloidosis: Andrea Havasi

12:30 pm: Lunch

2:00 pm: The Future

1. Overview of the novel treatments in Multiple Myeloma: Christopher Venner

2. Monoclonal Gammopathy of Clinical Significance: Jean-Paul Fermand

3:15 pm: IKMG future directions and closing remarks

3:45 pm: Break

4-6:00 pm: Board meeting

THANKS

This program is made possible through unrestricted grants from:

PLATINE
AMGEN

CELGENE
JANSSEN
TAKEDA

THE BINDING SITE

SILVER
MYELOME CANADA

as well as a contribution of TOURISME MONTREAL